APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
APIE Therapeutics appoints Debra K. Bowes, MBEE and Seth Hetherington, M.D. to the positions of chief business officer and chief medical officer, respectively.
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.
APIE Therapeutics Expands Board of Directors with Appointment of Dr. Diane Jorkasky
Diane K. Jorkasky, M.D. FACP brings over three decades of experience in all stages of clinical development to the APIE Therapeutics board.
RTI International Licenses Portfolio of Compounds to APIE Therapeutics
The agreement advances APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease
